The prevalence of neuropathic pain is high after treatment for breast cancer: A systematic review

Pain

Volumn 158, Issue 11, 2017, Pages 2082-2091

  Ilhan, Emre ^a   Chee, Edwin ^a   Hush, Julia ^a   Moloney, Niamh ^a  

^a MACQUARIE UNIVERSITY   (Australia)

Author keywords

Assessment methods; Breast cancer; Cancer; Neuropathic pain; Prevalence

Indexed keywords

BREAST CANCER; CANCER STAGING; CANCER THERAPY; CINAHL; COCHRANE LIBRARY; EARLY CANCER; EMBASE; FEMALE; HUMAN; MEDLINE; META ANALYSIS (TOPIC); NEUROPATHIC PAIN; PREVALENCE; PRIORITY JOURNAL; QUESTIONNAIRE; REVIEW; SCREENING; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; WEB OF SCIENCE; ANALGESIA; BREAST TUMOR; COMPLICATION; FACTUAL DATABASE; NEURALGIA; PAIN MEASUREMENT; STATISTICS AND NUMERICAL DATA;

BREAST NEOPLASMS; DATABASES, FACTUAL; FEMALE; HUMANS; META-ANALYSIS AS TOPIC; NEURALGIA; PAIN MANAGEMENT; PAIN MEASUREMENT; PREVALENCE; SURVEYS AND QUESTIONNAIRES;

EID: 85040796661     PISSN: 03043959     EISSN: 18726623     Source Type: Journal    
DOI: 10.1097/j.pain.0000000000001004     Document Type: Review

References (54)

1. Abdallah FW, Morgan PJ, Cil T, Escallon JM, Semple JL, Chan VW. Comparing the DN4 tool with the IASP grading system for chronic neuropathic screening after breast tumour resection with and without paravertebral blocks: a prospective 6-month validation study. PAIN 2015; 156:740-9.
2. Albi-Felzer A, Mouret-Fourme EE, Hamouda S, Motamed C, Dubois PY, Jouanneau L, Jayr C. A double-blind randomised trial of wound and intercostal space infiltration with ropivacaine during breast cancer surgery: effects on chronic postoperative pain. Anesthesiology 2013; 118:318-26.
3. Andersen K, Kehlet H. Persistent pain after breast cancer treatment: a critical review of risk factors and strategies for prevention. J Pain 2011; 12:725-46.
4. Andersen KG, Aasvang EK, Kroman N, Kehlet H. Intercostobrachial nerve handling and pain after axillary lymph node dissection for breast cancer. Acta Anaesthesiol Scand 2014;58:1240-8.
5. Andersen KG, Duriaud HM, Aasvang EK, Kehlet H. Association between sensory dysfunction and pain 1 week after breast cancer surgery: a psychophysical study. Acta Anaesthesiol Scand 2016;60:259-69.
6. Andersen KG, Duriaud HM, Jensen HE, Kroman N, Kehlet H. Predictive factors for the development of persistent pain after breast cancer surgery. PAIN 2015;156:2413-22.
7. Andersen KG, Jensen MB, Tvedskov TF, Kehlet H, Gä rtner R, Kroman N. Persistent pain, sensory disturbance and functional impairment after immediate or delayed axillary lymph node dissection. Eur J Surg Oncol 2013;39:31-5.
8. Australian Institute of Health &Welfare, Cancer Australia. Breast cancer in Australia: an overview. Canberra: AIHW, 2012.
9. Barendregt JJ, Suhail AD, Lee YY, Norman RE, Vos T. Meta-analysis of prevalence. J Epidemiol Community Health 2013;67:974-8.
10. Belfer I, Schreiber KL, Shaffer JR, Shnol H, Blaney K, Morando A, Englert D, Greco C, Brufsky A, Ahrendt G, Kehlet H, Edwards RR, Bovbjerg DH. Persistent postmastectomy pain in breast cancer survivors: analysis of clinical, demographic, and psychosocial factors. J Pain 2013;14: 1185-95.
11. Bennett MI. The LANSS pain scale: the Leeds assessment of neuropathic symptoms and signs. PAIN 2001;92:147-57.
12. Bennett MI. Effectiveness of antiepileptic or antidepressant drugs when added to opioids for cancer pain: systematic review. PalliatMed 2011;25: 553-9.
13. Bennett MI, Attal N, Backonja MM, Baron R, Bouhassira D, Freynhagen R, Scholz J, Tö lle TR, Wittchen HU, Jensen TS. Using screening tools to identify neuropathic pain. PAIN 2007;127:199-203.
14. Bennett MI, Rayment C, Hjermstad M, Aass N, Caraceni A, Kaasa S. Prevalence and aetiology of neuropathic pain in cancer patients: a systematic review. PAIN 2012;153:359-65.
15. Bennett MI, Smith BH, Torrance N, Potter J. The S-LANSS score for identifying pain of predominantly neuropathic origin: validation for use in clinical and postal research. PAIN 2005;6:149-58.
16. Bokhari FN, McMillan DE, McClement S, Daeninck PJ. Pilot study of a survey to identify the prevalence of and risk factors for chronic neuropathic pain following breast cancer surgery. Oncol Nurs Forum 2012;39:e141-9.
17. Bouhassira D, Attal N, Alchaar H, Boureau F, Brochet B, Bruxelle J, Cunin G, Fermanian J, Ginies P, Grun-Overdyking A, Jafari-Schluep H, Lante ri-Minet M, Laurent B, Mick G, Serrie A, Valade D, Vicaut E. Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4). PAIN 2005;114:29-36.
18. Bredal SI, Smeby NA, Ottesen S, Warncke T, Schlichting E. Chronic pain in breast cancer survivors: comparison of psychosocial, surgical, and medical characteristics between survivors with and without pain. J Pain Symptom Manage 2014;48:852-62.
19. Breivik H, Cherny N, Collett B, de Conno F, Filbet M, Foubert A, Cohen R, Dow L. Cancer-related pain: a pain-European survey of prevalence, treatment, and patient attitudes. Ann Oncol 2009;20:1420-33.
20. Bruce J, Thornton AJ, Powell R, Johnston M, Wells M, Heys SD, Thompson AM, Cairns Smith W, Chambers WA, Scott NW; Recovery Study Group. Psychological, surgical, and sociodemographic predictors of pain outcomes after breast cancer surgery: a population-based cohort study. PAIN 2014;155:232-43.
21. Cooney MA, Culleton-Quinn E, Stokes E. Current knowledge of pain after breast cancer treatment: a systematic review. Pain Manag Nurs 2013;14: 110-23.
22. Deandrea S, Montanari M, Moja L, Apolone G. Prevalence of undertreatment in cancer pain. A review of published literature. Ann Oncol 2008;19:1985-91.
23. Demant DT, Lund K, Vollert J, Maier C, Segerdahl M, Finnerup NB, Jensen TS, Sindrup SH. The effect of oxcarbazepine in peripheral neuropathic pain depends on pain phenotype: a randomised, doubleblind, placebo-controlled phenotype-stratified study. PAIN 2014;155: 2263-73.
24. Duale C, Ouchchane L, Schoeffler P; Edonis Investigating Group, Dubray C. Neuropathic aspects of persistent postsurgical pain: a French multicenter survey with a 6-month prospective follow-up. J Pain 2014; 15:e1-24.
25. Dworkin R, O'Connor A, Audette J, Baron R, Gourlay GK, Haanpä ä ML, Kent JL, Krane EJ, Lebel AA, Levy RM, Mackey SC, Mayer J, Miaskowski C, Raja SN, Rice AS, Schmader KE, Stacey B, Stanos S, Treede RD, Turk DC, Walco GA, Wells CD. Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clan Proc 2010;85:S3-S14.
26. Dworkin R, O'Connor A, Kent J, Mackey SC, Raja SN, Stacey BR, Levy RM, Backonja M, Baron R, Harke H, Loeser JD, Treede RD, Turk DC, Wells CD. International association for the study of pain neuropathic pain special interest group. Interventional management of neuropathic pain: NeuPSIG recommendations. PAIN 2013;154:2249-61.
27. Dworkin RH, O'Connor AB, Backonja M, Farrar JT, Finnerup NB, Jensen TS, Kalso EA, Loeser JD, Miakowski C, Nurmikko TJ, Portenoy RK, Rice AS, Stacey BR, Treede RD, Turk DC, Wallace MS. Pharmacologic management of neuropathic pain: evidence-based recommendations. PAIN 2007;132:237-51.
28. Fainsinger RL, Nekolaichuk CL, Lawlor PG, Neumann CM, Hanson J, Vigano A. A multicenter study of the revised Edmonton Staging System for classifying cancer pain in advanced cancer patients. J Pain Symptom Manage 2005;29:224-37.
29. Finnerup N, Attal N, Haroutounian S, McNicol E, Baron R, Dworkin RH, Gilron I, Haanpä ä M, Hansson P, Jensen TS, Kamerman PR, Lund K, Moore A, Raja SN, Rice AS, Rowbotham M, Sena E, Siddall P, Smith BH, Wallace M. Pharmacotherapy for neuropathic pain in adults: systematic review, meta-analysis and updated NeuPSIG recommendations. Lancet Neurol 2015;14:162-73.
30. Freynhagen R, Baron R, Gockel U, Tö lle TR. PainDETECT: a new screening questionnaire to identify neuropathic components in patients with back pain. Curr Med Res Opin 2006;22:1911-20.
31. Golan-Vered Y, Pud D. Chemotherapy-induced neuropathic pain and its relation to cluster symptoms in breast cancer patients treated with paclitaxel. Pain Pract 2013;13:46-52.
32. Haanpä ä M, Attal N, Backonja M, Baron R, Bennett M, Bouhassira D, Cruccu G, Hansson P, Haythornthwaite JA, Iannetti GD, Jensen TS, Kauppila T, Nurmikko TJ, Rice AS, Rowbotham M, Serra J, Sommer C, Smith BH, Treede RD. NeuPSIG guidelines on neuropathic pain assessment. PAIN 2011;152:14-27.
33. Hoy D, Brooks P, Woolf A, Blyth F, March L, Bain C, Baker P, Smith E, Buchbinder R. Assessing risk of bias in prevalence studies: modification of an existing tool and evidence of interrater agreement. J Clin Epidemiol 2012;65:934-9.
34. Jones D, Zhao F, Brell J, Lewis MA, Loprinzi CL, Weiss M, Fisch MJ. Neuropathic symptoms, quality of life, and clinician perception of patient care in medical oncology outpatients with colorectal, breast, lung, and prostate cancer. J Cancer Surviv 2015;9:1-10.
35. Juhl AA, Christiansen P, Damsgaard TE. Persistent pain after breast cancer treatment: a questionnaire-based study on the prevalence, associated treatment variables, and pain type. J Breast Cancer 2016; 19:447-54.
36. Jung BF, Ahrendt GM, Oaklander AL, Dworkin RH. Neuropathic pain following breast cancer surgery: proposed classification and research update. PAIN 2003;104:1-13.
37. Kojima KY, Kitahara M, Matoba M, Shimoyama N, Uezono S. Survey on recognition of post-mastectomy pain syndrome by breast specialist physician and present status of treatment in Japan. Breast Cancer 2012;30:30.
38. Leidenius M, Leivonen M, Vironen J, Von Smitten K. The consequences of long-time arm morbidity in node-negative breast cancer patients with sentinel node biopsy or axillary clearance. J Surg Oncol 2005;92:23-31.
39. Macdonald L, Bruce J, Scott NW, Smith WCS, Chambers WA. Longterm follow-up of breast cancer survivors with post-mastectomy pain syndrome. Br J Cancer 2005;92:225-30.
40. Mohamed SA, Abdel-Ghaffer HS. Effect of the addition of clonidine to locally administered bupivacaine on acute and chronic postmastectomy pain. J Clin Anesth 2013;25:20-7.
41. Mulvey MR, Rolke R, Klepstad P, Caraceni A, Fallon M, Colvin L, Laird B, Bennett MI. IASP Cancer Pain SIG and the EAPC Research Network. Confirming neuropathic pain in cancer patients: applying theNeuPSIG grading system in clinical practice and clinical practice. PAIN 2014;155:859-63.
42. Nijs J, Leysen L, Adriaenssens N, Ferrandiz AME, Devoogdt N, Tassenoy A, Ickmans K, Goubert D, van Wilgen CP, Wijma AJ, Kuppens K, Hoelen W, Hoelen A, Moloney N, Meeus M. Pain following cancer treatment: guidelines for the clinical classification of predominant neuropathic, nociceptive and central sensitization pain. Acta Oncol 2016;55:659-63.
43. Oldenmenger WH, Smitt PAS, van Dooren S, Stoter G, van der Rijt CC. A systematic review on barriers hindering adequate cancer pain management and interventions to reduce them: a critical appraisal. Eur J Cancer 2009;45:1370-40.
44. Padua L, Briani C, Truini A, Aprile I, Bouhassira D, Cruccu G, Jann S, Nobile-Orazio E, Pazzaglia C, Morini A, Mondelli M, Ciaramitaro P, Cavaletti G, Cocito D, Fazio R, Santoro L, Galeotti F, CarpoM, Plasmati R, Benedetti L, Schenone A. Consistence and discrepancy of neuropathic pain screening tools DN4 and ID-Pain. Neurol Sci 2013;34:373-7.
45. Passavanti MB, Pace MC, Barbarisi A, D'Andrea F, Grella E, Nicoletti GF, Aurillo C. Pain and sensory dysfunction after breast cancer surgery: neurometer CPT Evaluation. Anticancer Res 2006;26:3839-44.
46. Pereira S, Fontes F, Sonin T, Dias T, Fragoso M, Castro-Lopes JM, Lunet N. Neurological complications of breast cancer: a prospective cohort study. Breast 2015;24:582-7.
47. Reyes-Gibby C, Morrow PK, Bennett MI, Jensen MP, Shete S. Neuropathic pain in breast cancer survivors: using the ID pain as a screening tool. J Pain Symptom Manage 2010;39:882-9.
48. Sheriden D, Foo I, O'Shea H, Gillanders D, Williams L, Fallon M, Colvin L. Long-term follow-up of pain and emotional characteristics of women after surgery for breast cancer. J Pain Symptom Manage 2012;44:608-14.
49. Singletary SE, Allred C, Ashley P, Bassett LW, Berry D, Bland KI, Borgen PI, Clark G, Edge SB, Hayes DF, Hughes LL, Hutter RVP, Morrow M, Page DL, Recht A, Theriault RL, Thor A, Weaver DL, Wieand S, Greene FL. Revision of the American Joint Committee on Cancer staging for breast cancer. J Clin Oncol 2002;20:3628-36.
50. Steegers MA, Wolters B, Evers AW, Strobbe L, Wilder-Smith OH. Effect of axillary lymph node dissection on prevalence and intensity of chronic and phantom pain after breast cancer surgery. PAIN 2008;9:813-22.
51. Steyaert A, Forget P, Dubois V, Lavand'homme P, De Kock M. Does the perioperative analgesic/anesthetic regimen influence the prevalence of long-term chronic pain after mastectomy? J Clin Anesth 2016;33:20-5.
52. Treede RD, Jensen TS, Campbell JN, Cruccu G, Dostrovsky JO, Griffin JW, Hansson P, Hughes R, Nurmikko T, Serra J. Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurology 2008;70:1630-5.
53. Vilholm OJ, Cold S, Rasmussen L, Sindrup SH. Sensory function and pain in a population of patients treated for breast cancer. Acta Anaesthesiol Scand 2009;53:800-6.
54. Yang EJ, Park WB, Seo KS, Kim SW, Heo CY, Lim JY. Longitudinal change of treatment-related upper limb dysfunction and its impact on late dysfunction in breast cancer survivors: a prospective cohort study. J Surg Oncol 2010;101:84-91.